Overview of benefit/risk of biological agents

Anna K. Imperato, Clifton Bingham, Steven B. Abramson

Research output: Contribution to journalArticle

Abstract

Targeted tumor necrosis factor-α antagonists, first approved by the FDA in 1998, have had a significant impact on the treatment of patients with rheumatoid arthritis. In general, the benefit/risk ratio for these agents and the IL-1 receptor antagonist, anakinra, has been quite favorable. However, infrequent adverse events can be serious and require continued Pharmacovigilance. Infections, particularly tuberculosis and less commonly fungal infections, are among the most serious adverse events, especially given delays in diagnosis due to subtle or atypical presentations. Questions have also arisen regarding whether anti-TNF-α agents increase the risk of lymphoma, a complicated issue confounded by the multiple risk factors for lymphoma in patients with rheumatoid arthritis and low observed incidence rates of lymphoma, requiring prolonged monitoring. Additional rare reported complications include systemic lupus erythematosus-like syndromes, congestive heart failure and demyelinating syndromes (including cases resembling progressive multifocal leukoencephalopathy). Ongoing post-marketing surveillance of these and other serious adverse events is necessary to determine the true incidence rates, and whether a reassessment of the overall risk-benefit of tumor necrosis factor-α antagonists will be required.

Original languageEnglish (US)
JournalClinical and Experimental Rheumatology
Volume22
Issue number5 SUPPL. 35
StatePublished - 2004
Externally publishedYes

Fingerprint

Biological Factors
Lymphoma
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Interleukin 1 Receptor Antagonist Protein
Progressive Multifocal Leukoencephalopathy
Pharmacovigilance
Interleukin-1 Receptors
Mycoses
Incidence
Marketing
Systemic Lupus Erythematosus
Tuberculosis
Heart Failure
Odds Ratio
Infection
Therapeutics

Keywords

  • Demyelination
  • Drug-induced lupus
  • Heart failure
  • Infections
  • Lymphoma
  • Rheumatoid arthritis
  • TNF-α antagonists

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Imperato, A. K., Bingham, C., & Abramson, S. B. (2004). Overview of benefit/risk of biological agents. Clinical and Experimental Rheumatology, 22(5 SUPPL. 35).

Overview of benefit/risk of biological agents. / Imperato, Anna K.; Bingham, Clifton; Abramson, Steven B.

In: Clinical and Experimental Rheumatology, Vol. 22, No. 5 SUPPL. 35, 2004.

Research output: Contribution to journalArticle

Imperato, AK, Bingham, C & Abramson, SB 2004, 'Overview of benefit/risk of biological agents', Clinical and Experimental Rheumatology, vol. 22, no. 5 SUPPL. 35.
Imperato, Anna K. ; Bingham, Clifton ; Abramson, Steven B. / Overview of benefit/risk of biological agents. In: Clinical and Experimental Rheumatology. 2004 ; Vol. 22, No. 5 SUPPL. 35.
@article{915e1f5dcb9d4dddac8bbbecdf8d14f3,
title = "Overview of benefit/risk of biological agents",
abstract = "Targeted tumor necrosis factor-α antagonists, first approved by the FDA in 1998, have had a significant impact on the treatment of patients with rheumatoid arthritis. In general, the benefit/risk ratio for these agents and the IL-1 receptor antagonist, anakinra, has been quite favorable. However, infrequent adverse events can be serious and require continued Pharmacovigilance. Infections, particularly tuberculosis and less commonly fungal infections, are among the most serious adverse events, especially given delays in diagnosis due to subtle or atypical presentations. Questions have also arisen regarding whether anti-TNF-α agents increase the risk of lymphoma, a complicated issue confounded by the multiple risk factors for lymphoma in patients with rheumatoid arthritis and low observed incidence rates of lymphoma, requiring prolonged monitoring. Additional rare reported complications include systemic lupus erythematosus-like syndromes, congestive heart failure and demyelinating syndromes (including cases resembling progressive multifocal leukoencephalopathy). Ongoing post-marketing surveillance of these and other serious adverse events is necessary to determine the true incidence rates, and whether a reassessment of the overall risk-benefit of tumor necrosis factor-α antagonists will be required.",
keywords = "Demyelination, Drug-induced lupus, Heart failure, Infections, Lymphoma, Rheumatoid arthritis, TNF-α antagonists",
author = "Imperato, {Anna K.} and Clifton Bingham and Abramson, {Steven B.}",
year = "2004",
language = "English (US)",
volume = "22",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5 SUPPL. 35",

}

TY - JOUR

T1 - Overview of benefit/risk of biological agents

AU - Imperato, Anna K.

AU - Bingham, Clifton

AU - Abramson, Steven B.

PY - 2004

Y1 - 2004

N2 - Targeted tumor necrosis factor-α antagonists, first approved by the FDA in 1998, have had a significant impact on the treatment of patients with rheumatoid arthritis. In general, the benefit/risk ratio for these agents and the IL-1 receptor antagonist, anakinra, has been quite favorable. However, infrequent adverse events can be serious and require continued Pharmacovigilance. Infections, particularly tuberculosis and less commonly fungal infections, are among the most serious adverse events, especially given delays in diagnosis due to subtle or atypical presentations. Questions have also arisen regarding whether anti-TNF-α agents increase the risk of lymphoma, a complicated issue confounded by the multiple risk factors for lymphoma in patients with rheumatoid arthritis and low observed incidence rates of lymphoma, requiring prolonged monitoring. Additional rare reported complications include systemic lupus erythematosus-like syndromes, congestive heart failure and demyelinating syndromes (including cases resembling progressive multifocal leukoencephalopathy). Ongoing post-marketing surveillance of these and other serious adverse events is necessary to determine the true incidence rates, and whether a reassessment of the overall risk-benefit of tumor necrosis factor-α antagonists will be required.

AB - Targeted tumor necrosis factor-α antagonists, first approved by the FDA in 1998, have had a significant impact on the treatment of patients with rheumatoid arthritis. In general, the benefit/risk ratio for these agents and the IL-1 receptor antagonist, anakinra, has been quite favorable. However, infrequent adverse events can be serious and require continued Pharmacovigilance. Infections, particularly tuberculosis and less commonly fungal infections, are among the most serious adverse events, especially given delays in diagnosis due to subtle or atypical presentations. Questions have also arisen regarding whether anti-TNF-α agents increase the risk of lymphoma, a complicated issue confounded by the multiple risk factors for lymphoma in patients with rheumatoid arthritis and low observed incidence rates of lymphoma, requiring prolonged monitoring. Additional rare reported complications include systemic lupus erythematosus-like syndromes, congestive heart failure and demyelinating syndromes (including cases resembling progressive multifocal leukoencephalopathy). Ongoing post-marketing surveillance of these and other serious adverse events is necessary to determine the true incidence rates, and whether a reassessment of the overall risk-benefit of tumor necrosis factor-α antagonists will be required.

KW - Demyelination

KW - Drug-induced lupus

KW - Heart failure

KW - Infections

KW - Lymphoma

KW - Rheumatoid arthritis

KW - TNF-α antagonists

UR - http://www.scopus.com/inward/record.url?scp=4944234410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4944234410&partnerID=8YFLogxK

M3 - Article

VL - 22

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5 SUPPL. 35

ER -